MiR-492 as an Important Biomarker for Early Diagnosis and Targeted Treatment in Different Cancers

(E-pub Ahead of Print)

Author(s): Eskandar Taghizadeh*, Forough Taheri, Daryoush Rostami, Pedram Ghorbani Renani, Gordon A Ferns, Alireza Pasdar, Majid Ghayour Mobarhan

Journal Name: Current Cancer Therapy Reviews

Become EABM
Become Reviewer


Recent studies have been led to a more detailed understanding of the roles played by microRNAs in health and disease, and their potential use as biomarkers in physiological and pathophysiological processes involving cancer initiation and progression. MiR-492 is encoded by a pseudogene, has a key role in some human cancer cells and its overexpression in tissues, and it has been proposed that it can be used as a good biomarker for management and early diagnosis of some cancers including breast cancer, colorectal and ovarian cancer hepatocellular cancer, retinoblastoma and pancreatic cancer. The aim of this review was to summarize the data of MiR-492 for early diagnosis and treatment some types of related cancers.

Keywords: MiR-492, breast cancer, microRNAs, colorectal cancer, cancer, Therapies

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573394716666200309124048

Article Metrics

PDF: 5